Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: numb (113)

Carboplatin (AUC4)-Gemcitabine (day 1) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC4)-GEMCITABINE (day 1) Retreat Regimen • Ovary-Carboplatin (AUC4)-Gemcitabine (1) Indication • Recurrent platinum sensitive ovarian
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC4-Gemcitabineday1Retreat.pdf

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (twice weekly)-Daratumumab-Dexamethasone Indication • Dara
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Daratumumab SC Ver1

Description: Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for treati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

Psoralen ultraviolet light A (PUVA) treatment - Tablet or capsule - patient information

Description: This factsheet explains what psoralen ultraviolet light A (PUVA) treatment is, how to prepare for it and the benefits and risks
Url: /Media/UHS-website-2019/Patientinformation/Skin/Psoralen-ultraviolet-light-A-PUVA-treatment-Tablet-or-capsule-4035-PIL.pdf

MP000 028 Cellular pathology user handbook v24

Description: University Hospital Southampton NHS Foundation Trust PATHOLOGY DIRECTORATE Cellular Pathology (Management) MP 000 028 Revision 2
Url: /Media/UHS-website-2019/Docs/Services/Pathology/Cell-path/MP000-028-Cellular-pathology-user-handbook-v24.pdf

Isatuximab VRD weekly

Description: Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Regimen Myeloma – Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenal
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

Your balance assessment appointment - patient information

Description: This factsheet explains what to expect at your balance assessment appointment and how to prepare for it.
Url: /Media/UHS-website-2019/Patientinformation/Audiology/Your-balance-assessment-appointment-2760-PIL.pdf

Carboplatin (AUC4)-Gemcitabine (day 1, 8) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC4)-GEMCITABINE (day 1, 8) Retreat Regimen • Ovary-Carboplatin (AUC4)-Gemcitabine (1, 8) Retreat Indication •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC4-Gemcitabineday18Retreat.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

21 to 30 of 143

Previous 1 2 3 4 5 … Next